查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004887

更年期熱潮紅市場：依產品類型、銷售管道和年齡層別分類－2026-2032年全球市場預測

Menopausal Hot Flashes Market by Product Type, Distribution Channel, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，更年期熱潮紅市場價值將達到 92 億美元，到 2026 年將成長至 98.5 億美元，到 2032 年將達到 143.9 億美元，年複合成長率為 6.59%。

主要市場統計數據
基準年 2025 92億美元
預計年份：2026年 98.5億美元
預測年份 2032 143.9億美元
複合年成長率 (%) 6.59%

一個簡潔、情境化的框架，將臨床症狀管理、治療方法方案和商業性優先事項結合起來，以便所有相關人員做出明智的決策。

更年期熱潮紅仍然是臨床和商業性持續存在的挑戰，它交織著臨床症狀管理、患者生活品質以及不斷發展的治療創新。本執行摘要全面概述了當前形勢，涵蓋治療方法、通路、人口統計因素、區域趨勢以及影響藥物獲取和分銷的監管和貿易環境。其目的是提供一個連貫的敘述，以支援產品開發、醫學事務、商業策略和供應鏈規劃等方面的策略決策。

臨床實踐、病人參與和分銷生態系統的現代變革正在重新定義更年期症狀的治療策略和商業模式。

在病患期望、科學進步和醫療服務模式不斷發展的推動下，更年期熱潮紅的管理格局正在改變。病患自主權的提升和數位化健康工具的運用正在改變症狀的報告和管理方式，而新的臨床證據也拓展了傳統荷爾蒙療法以外的有效干預選擇。因此，臨床醫生擴大採用綜合療法，結合生活方式調整、輔助療法和標靶非荷爾蒙藥物治療。

藥品價格調整對藥品採購、生產經濟和分銷通路定價趨勢的綜合影響，以及對供應連續性和准入策略的影響。

2025年的政策環境，特別是美國國內的關稅趨勢，對更年期保健品生產商和經銷商的供應鏈、籌資策略和成本結構產生了一系列累積影響。活性成分、經皮和外用製劑專用成分以及進口植物性原料的關稅調整改變了採購成本的計算方式，促使企業重新評估其供應商多元化策略，並探索近岸外包和替代採購方式以維持供應的連續性。

將治療領域、多通路分銷和年齡層患者群體連結起來的詳細細分分析，能夠制定精準的目標定位和產品策略。

精細的市場細分分析揭示了不同治療領域、分銷管道和人口統計群體之間的不同趨勢，從而為產品定位和商業策略提供了直接的洞察。就產品類型而言，以黑升麻萃取物、當歸根萃取物和異黃酮萃取物等植物性化合物為代表的輔助療法，持續吸引尋求處方箋藥和被視為天然療法的患者，同時也面臨臨床證據差異和監管不力等挑戰。荷爾蒙療法仍然是許多患者的基礎療法，雌激素-黃體素組合藥物、雌激素單藥療法和選擇性雌激素受體調節（SERMs）各自具有不同的安全性特徵和處方情況。雌激素療法本身分為口服、外用和經皮給藥途徑，其中經皮給藥因其可減少全身暴露和調整劑量而更受青睞。

區域趨勢和主要區域的監管差異決定了治療方法的採納、分發策略和證據生成的優先事項。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的監管方式、處方實踐和分銷基礎設施都產生了深遠的影響，每個地區都具有獨特的戰略意義。在美洲，完善的臨床指南和成熟的支付方環境為差異化的治療定位鋪平了道路，但區域間在醫療服務可及性和保險覆蓋範圍方面的差異，使得個性化的市場准入和患者支持計劃成為必要。同時，歐洲、中東和非洲地區擁有廣泛的管理體制和支付方模式，需要靈活的監管策略和彈性價格設定方式，以應對公共衛生優先事項並適應不同醫療保健系統的能力。

競爭格局洞察，重點在於臨床嚴謹性、供應鏈靈活性以及透過與分銷管道的夥伴關係的策略差異化。

更年期治療市場的競爭格局由多家公司組成，包括老牌製藥公司、專業生物技術公司、植物來源和輔助療法生產商，以及數位化原生零售商和服務供應商。老牌製藥公司憑藉其豐富的臨床經驗、廣泛的監管能力和整合的供應鏈，在荷爾蒙和非荷爾蒙藥物領域保持著穩固的地位。同時，小規模但富有創新精神的公司往往透過針對性的作用機制研究、提高耐受性或開發新型給藥技術來脫穎而出。

高階主管面臨的策略和營運挑戰是，如何協調臨床證據、通路策略和供應鏈彈性，從而建立永續的競爭優勢。

產業領導者應優先考慮整合證據產生、病人參與和供應鏈韌性的綜合策略，以最大限度地發揮不斷變化的臨床和商業性趨勢的潛力。首先，投資於針對特定劑量和分子的、旨在評估安全性、耐受性和患者報告結局 (PRO) 的靶向臨床試驗，從而提高處方集採納率和臨床醫生接受度。同時，開發以患者為中心的支持項目，將醫療主導的護理與數位化追蹤相結合，透過教育和症狀追蹤工具提高用藥依從性和長期治療效果。

一個強大的混合方法研究框架，整合了臨床醫生訪談、監管分析和供應鏈檢驗，從而得出引人注目的策略見解。

本分析的研究途徑利用了多方面的定性和定量數據，並交叉引用了同行檢驗的臨床文獻、監管公告、供應鏈文件和相關人員訪談，以構建全面平衡的觀點。主要研究包括對臨床醫生、藥房經理和供應鏈負責人進行結構化訪談，以揭示真實的臨床實踐模式、通路的經濟效益和營運限制。次要研究整合了權威的臨床研究、指南更新和政策變化，以闡明治療決策和安全考量的背景。

整合治療方案、營運韌性和證據優先性，制定切實可行的藍圖，為相關人員。

總之，在現代社會，應對更年期熱潮紅需要採取多管齊下的策略，整合臨床證據、以病人為中心的醫療服務以及穩健的商業運作。治療方案包括輔助草藥療法、多種給藥途徑的成熟荷爾蒙療法以及日益普及的非荷爾蒙藥物療法，每種療法在安全性、依從性和通路適用性方面都有其自身的考慮。同時，政策變化和貿易趨勢凸顯了積極主動的供應鏈規劃和靈活的籌資策略對於確保藥物可近性和可預測性的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：更年期熱潮紅市場：依產品類型分類

  • 輔助療法
    • 黑升麻
    • 安吉莉卡
    • 異黃酮
  • 荷爾蒙療法
    • 雌激素-黃體素聯合治療
    • 雌激素療法
      • 口服雌激素
      • 局部雌激素
      • 經皮雌激素
    • 選擇性雌激素受體調節
  • 非荷爾蒙療法
    • 可樂定
    • Gabapentin
    • SSRI
      • Fluoxetine
      • 帕羅西汀
      • 舍曲林

第9章：更年期熱潮紅市場：依通路分類

  • 診所
  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 線上零售商
    • 企業網站
    • 電子商務平台

第10章：更年期熱潮紅市場：依年齡層別分類

  • 40-50歲
  • 51-60歲
  • 60歲或以上

第11章 更年期熱潮紅市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 更年期熱潮紅市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：更年期熱潮紅市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國更年期熱潮紅市場

第15章：中國更年期熱潮紅市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Besins Healthcare
  • Cipla Ltd.
  • Endoceutics Inc.
  • Ferring International Center SA
  • GlaxoSmithKline plc
  • Hisamitsu Pharmaceutical Co., Ltd.
  • Lupin Ltd.
  • Millendo Therapeutics, Inc.
  • Mithra Pharmaceuticals SA
  • Novartis AG
  • Novo Nordisk A/S
  • Organon & Co.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theramex Ltd.
  • Viatris Inc.
Product Code: MRR-742BD51814A1

The Menopausal Hot Flashes Market was valued at USD 9.20 billion in 2025 and is projected to grow to USD 9.85 billion in 2026, with a CAGR of 6.59%, reaching USD 14.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.20 billion
Estimated Year [2026] USD 9.85 billion
Forecast Year [2032] USD 14.39 billion
CAGR (%) 6.59%

Concise contextual framing that aligns clinical symptom management, therapeutic choices, and commercial priorities for informed decision-making across stakeholders

Menopausal hot flashes represent a persistent clinical and commercial challenge that intersects clinical symptom management, patient quality of life, and evolving therapeutic innovation. This executive summary synthesizes the contemporary landscape spanning therapeutic modalities, distribution pathways, demographic considerations, regional dynamics, and the regulatory and trade environment shaping access and adoption. The objective is to provide a coherent narrative that informs strategic decisions across product development, medical affairs, commercial strategy, and supply chain planning.

The narrative that follows places emphasis on both clinical relevance and market-facing implications, balancing patient-centered outcomes with pragmatic considerations for manufacturers, payers, and providers. It identifies how therapeutic choices-from complementary and hormonal approaches to a growing array of non-hormonal pharmacotherapies-align with patient preferences, safety considerations, and prescribing trends. Moreover, the summary highlights how distribution and demographic segmentation drive differentiated uptake and service delivery models.

By framing these elements in an integrated manner, the introduction prepares readers for deeper analysis of structural shifts, policy impacts, and actionable recommendations. The intent is to equip stakeholders with the contextual understanding required to prioritize investments, adapt commercialization plans, and engage meaningfully with clinicians and patient communities.

Contemporary shifts in clinical practice, patient engagement, and distribution ecosystems are converging to redefine therapeutic strategies and commercial models for menopausal symptom management

The landscape for managing menopausal hot flashes is undergoing transformative shifts driven by patient expectations, scientific advances, and evolving care delivery models. Patient empowerment and digital health tools have altered how symptoms are reported and managed, while new clinical evidence has expanded the spectrum of viable interventions beyond traditional hormonal therapies. As a result, clinicians are increasingly integrating multi-modal approaches that combine lifestyle interventions, complementary modalities, and targeted non-hormonal pharmacotherapies.

Concurrently, regulatory scrutiny and safety narratives have prompted more nuanced prescribing behavior, encouraging the use of individualized treatment plans that weigh benefits and risks with greater granularity. These changes are accompanied by supply chain reconfigurations and a surge in direct-to-patient distribution pathways, which shift competitive dynamics and raise expectations for convenience, transparency, and patient support services. The convergence of clinical, regulatory, and commercial vectors is therefore reshaping product life cycles, forcing manufacturers to adapt in real time and to prioritize evidence generation that demonstrates both efficacy and patient-centred value.

Taken together, these transformative shifts demand a strategic re-evaluation of innovation priorities and go-to-market approaches, emphasizing flexible delivery, robust patient engagement, and cross-functional alignment between clinical development, regulatory affairs, and commercial teams.

Comprehensive effects of tariff shifts on pharmaceutical sourcing, manufacturing economics, and channel pricing dynamics that influence supply continuity and access strategies

The policy environment in 2025, notably tariff developments within the United States, has introduced a range of cumulative effects that ripple through supply chains, procurement strategies, and cost structures for manufacturers and distributors serving menopausal health. Tariff adjustments on active pharmaceutical ingredients, specialty components for transdermal and topical formulations, and imported botanical raw materials have altered sourcing calculus, prompting firms to reassess supplier diversification and to explore nearshoring or secondary sourcing to maintain continuity of supply.

Furthermore, increased import duties have amplified the importance of cost containment initiatives, accelerating negotiations with contract manufacturers and incentivizing process improvements to offset incremental input costs. In parallel, distributors and clinics have had to revisit pricing differentials across channels, with implications for reimbursement discussions and patient access programs. While tariffs do not alter clinical efficacy or regulatory approvals, they influence commercial viability by changing total landed costs and may indirectly affect formulary positioning and the economics of promotional programs.

As a result, organizations are adopting a combination of tactical measures-such as renegotiated supplier contracts, inventory hedging, and greater transparency in cost-to-serve calculations-and strategic pathways, including technology-enabled supply chain visibility and supplier risk scoring. These responses aim to protect supply continuity and preserve margins while ensuring that therapeutic choice and patient access remain central to decision-making.

In-depth segmentation narrative connecting therapeutic categories, multi-channel distribution, and age-based patient cohorts to inform precision targeting and product strategy

A nuanced segmentation analysis reveals differentiated dynamics across therapeutic classes, channels, and demographic cohorts that directly inform product positioning and commercial tactics. When considering product type, complementary therapies such as botanical compounds-exemplified by extracts like black cohosh, dong quai, and isoflavones-continue to attract patients seeking non-prescription options and perceived natural remedies, but they also face variability in clinical evidence and regulatory scrutiny. Hormonal therapies remain a cornerstone for many patients, and within that class combined estrogen-progestin formulations, estrogen-only regimens, and selective estrogen receptor modulators each present distinct safety profiles and prescribing contexts. Estrogen therapy itself splits across oral, topical, and transdermal delivery mechanisms, with transdermal options often preferred when mitigating systemic exposure and tailoring dose delivery.

Non-hormonal therapies form a complementary suite, including agents such as clonidine, gabapentin, and selective serotonin reuptake inhibitors, where molecule-specific tolerability and off-label usage patterns shape clinician choice. Within SSRIs, individual agents like fluoxetine, paroxetine, and sertraline exhibit differences in interaction potential and side-effect profiles that influence patient adherence and long-term management. Transitioning to distribution channels, clinics play a critical role in initiating care and managing follow-up, hospital pharmacies-both private and public-serve as important dispensing and formulary decision points, and online retailers, encompassing company websites and broader e-commerce platforms, are expanding access and altering consumer purchasing behavior.

Age group segmentation further refines strategic priorities: patients aged 40 to 50 typically present at or approaching perimenopause with different symptom trajectories and information needs than those aged 51 to 60 who are often in the acute menopausal transition, while those above 60 may prioritize long-term safety and comorbidity management. Integrating these segmentation layers enables targeted clinical messaging, formulary positioning, and tailored patient support interventions that align therapeutic attributes with channel strengths and patient expectations.

Regional dynamics and regulatory diversity across major geographies that shape treatment adoption, distribution strategies, and evidence generation priorities

Regional dynamics exert a powerful influence on regulatory approaches, prescribing norms, and distribution infrastructures across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting distinct strategic implications. In the Americas, established clinical guidelines and a mature payer environment create pathways for differentiated therapeutic positioning, while regional variations in access and coverage necessitate tailored market entry and patient support programs. Conversely, the Europe Middle East & Africa region includes a wide spectrum of regulatory regimes and payer models, requiring adaptive regulatory strategies and flexible pricing approaches to accommodate public health priorities and heterogeneous healthcare system capabilities.

In Asia-Pacific, demographic trends and rapid expansion of digital health platforms are reshaping patient engagement and distribution models, with e-commerce and telemedicine increasingly serving as gateways to care. Moreover, local manufacturing capabilities and regional supply chain hubs may present opportunities for cost-effective sourcing and faster scale-up of new formulations. Across all regions, cultural attitudes toward complementary therapies and hormonal treatment safety perceptions influence uptake, while region-specific clinical practice patterns affect how products are recommended and monitored.

To be successful across these geographies, stakeholders must adopt regionally differentiated strategies that respect regulatory nuance, local clinical practice, and distribution channel maturity, while leveraging global evidence generation to build cross-border credibility and optimize regional adoption.

Competitive landscape insights highlighting strategic differentiation through clinical rigor, supply chain agility, and distribution channel partnerships

Competitive positioning in the menopausal therapeutic space reflects a mix of legacy pharmaceutical companies, specialized biotech players, manufacturers of botanical and complementary products, and digitally native retailers and service providers. Established pharmaceutical organizations leverage deep clinical experience, broad regulatory capabilities, and integrated supply chains to maintain presence across hormonal and non-hormonal categories, while smaller innovators often differentiate through targeted mechanism-of-action research, improved tolerability profiles, or novel delivery technologies.

At the same time, manufacturers of complementary therapies drive consumer interest and often act as entry points for patients seeking self-managed alternatives, but they must navigate variability in clinical substantiation and regulatory frameworks. Distribution innovators, including hospital pharmacy systems and online platforms, influence visibility and access, creating opportunities for manufacturers to develop channel-specific value propositions and co-created patient engagement programs. Strategic collaborations between clinical research teams and commercial stakeholders are increasingly common, with successful companies aligning early-stage evidence plans to anticipated reimbursement and formulary discussions.

In summary, companies that combine rigorous clinical evidence, adaptive supply chain strategies, and channel-tailored commercialization plans are best positioned to navigate the complexity of this therapeutic area and to capture durable clinical and commercial relevance.

Strategic and operational imperatives for senior leadership to align clinical evidence, channel strategies, and supply resilience for sustainable competitive advantage

Industry leaders should prioritize an integrative strategy that aligns evidence generation, patient engagement, and supply chain resilience to capitalize on evolving clinical and commercial dynamics. First, invest in targeted clinical studies that address safety, tolerability, and patient-reported outcomes for specific delivery modalities and molecules, thereby strengthening formulary and clinician acceptance. Concurrently, develop tailored patient support programs that bridge clinic-initiated care and digital follow-up, enhancing adherence and long-term outcomes through education and symptom tracking tools.

Operationally, diversify sourcing and build supplier redundancy to mitigate tariff-related and geopolitical risks, while implementing greater transparency in total cost-to-serve calculations to inform pricing and channel strategies. Commercially, design channel-specific go-to-market models that leverage hospital pharmacy partnerships for formulary inclusion, clinic relationships for prescriber education, and online platforms for direct-to-consumer engagement. Execute value-based pricing pilots where appropriate and engage payers early with real-world evidence demonstrating comparative effectiveness and quality-of-life improvements.

Finally, cultivate cross-functional teams that link clinical development, regulatory affairs, manufacturing, and commercial leadership to accelerate time-to-value and ensure that scientific advances translate into accessible, patient-centered therapeutic options.

Robust mixed-methods research framework integrating clinician interviews, regulatory analysis, and supply chain validation to produce defensible strategic insights

The research approach underpinning this analysis combined multi-source qualitative and quantitative inputs, triangulating peer-reviewed clinical literature, regulatory pronouncements, supply chain documentation, and stakeholder interviews to build a comprehensive and balanced perspective. Primary research included structured interviews with clinicians, pharmacy directors, and supply chain leaders to surface real-world practice patterns, channel economics, and operational constraints. Secondary research synthesized authoritative clinical studies, guideline updates, and policy changes to contextualize therapeutic decisions and safety considerations.

Data synthesis emphasized cross-validation across sources to mitigate bias and ensure robustness; clinical findings were compared against prescribing patterns and distribution flows, while supplier and tariff impacts were assessed through procurement records and industry reporting. The methodology prioritized transparency in assumptions and clarity on data provenance, and where gaps were identified, recommended targeted primary studies to resolve uncertainties. Ethical considerations and patient privacy were central to the primary research design, with insights anonymized and aggregated to protect confidentiality.

Overall, this mixed-methods approach provides a defensible foundation for the strategic insights and recommendations presented, enabling stakeholders to act with confidence while identifying areas that warrant deeper, bespoke investigation.

Synthesis of therapeutic choices, operational resilience, and evidence priorities that together form a practical roadmap for sustainable stakeholder impact

In conclusion, managing menopausal hot flashes in the current era requires a multifaceted strategy that blends clinical evidence, patient-centric delivery, and resilient commercial operations. Therapeutic options span complementary botanicals, established hormonal regimens across multiple delivery systems, and a growing set of non-hormonal pharmacotherapies, each with distinct considerations for safety, adherence, and channel fit. Simultaneously, policy changes and trade dynamics have underscored the need for proactive supply chain planning and flexible sourcing strategies to preserve access and predictability.

Strategic success will favor organizations that align rigorous evidence generation with targeted patient engagement, channel-specific commercialization, and operational agility. By adopting these imperatives, stakeholders can better meet clinician and patient expectations, navigate regulatory complexity, and maintain competitive positioning. The synthesis provided here is intended as a practical roadmap that supports prioritized action, continued learning, and iterative refinement as new data and regulatory developments emerge.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Menopausal Hot Flashes Market, by Product Type

  • 8.1. Complementary Therapy
    • 8.1.1. Black Cohosh
    • 8.1.2. Dong Quai
    • 8.1.3. Isoflavones
  • 8.2. Hormonal Therapy
    • 8.2.1. Combined Estrogen-Progestin Therapy
    • 8.2.2. Estrogen Therapy
      • 8.2.2.1. Oral Estrogen
      • 8.2.2.2. Topical Estrogen
      • 8.2.2.3. Transdermal Estrogen
    • 8.2.3. Selective Estrogen Receptor Modulators
  • 8.3. Non-Hormonal Therapy
    • 8.3.1. Clonidine
    • 8.3.2. Gabapentin
    • 8.3.3. SSRIs
      • 8.3.3.1. Fluoxetine
      • 8.3.3.2. Paroxetine
      • 8.3.3.3. Sertraline

9. Menopausal Hot Flashes Market, by Distribution Channel

  • 9.1. Clinics
  • 9.2. Hospital Pharmacies
    • 9.2.1. Private Hospitals
    • 9.2.2. Public Hospitals
  • 9.3. Online Retailers
    • 9.3.1. Company Websites
    • 9.3.2. E-Commerce Platforms

10. Menopausal Hot Flashes Market, by Age Group

  • 10.1. 40 To 50
  • 10.2. 51 To 60
  • 10.3. Above 60

11. Menopausal Hot Flashes Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Menopausal Hot Flashes Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Menopausal Hot Flashes Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Menopausal Hot Flashes Market

15. China Menopausal Hot Flashes Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AbbVie Inc.
  • 16.6. Astellas Pharma Inc.
  • 16.7. Bayer AG
  • 16.8. Besins Healthcare
  • 16.9. Cipla Ltd.
  • 16.10. Endoceutics Inc.
  • 16.11. Ferring International Center S.A.
  • 16.12. GlaxoSmithKline plc
  • 16.13. Hisamitsu Pharmaceutical Co., Ltd.
  • 16.14. Lupin Ltd.
  • 16.15. Millendo Therapeutics, Inc.
  • 16.16. Mithra Pharmaceuticals SA
  • 16.17. Novartis AG
  • 16.18. Novo Nordisk A/S
  • 16.19. Organon & Co.
  • 16.20. Pfizer Inc.
  • 16.21. Sun Pharmaceutical Industries Ltd.
  • 16.22. Teva Pharmaceutical Industries Ltd.
  • 16.23. Theramex Ltd.
  • 16.24. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MENOPAUSAL HOT FLASHES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MENOPAUSAL HOT FLASHES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY BLACK COHOSH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY BLACK COHOSH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY BLACK COHOSH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DONG QUAI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DONG QUAI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DONG QUAI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ISOFLAVONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ISOFLAVONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ISOFLAVONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMBINED ESTROGEN-PROGESTIN THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMBINED ESTROGEN-PROGESTIN THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMBINED ESTROGEN-PROGESTIN THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ORAL ESTROGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ORAL ESTROGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ORAL ESTROGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TOPICAL ESTROGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TOPICAL ESTROGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TOPICAL ESTROGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TRANSDERMAL ESTROGEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TRANSDERMAL ESTROGEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY TRANSDERMAL ESTROGEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLONIDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLONIDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLONIDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GABAPENTIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GABAPENTIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY FLUOXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PAROXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SERTRALINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPANY WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPANY WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPANY WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 40 TO 50, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 40 TO 50, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 40 TO 50, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 51 TO 60, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 51 TO 60, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY 51 TO 60, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ABOVE 60, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ABOVE 60, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY ABOVE 60, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 206. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 239. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 244. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 250. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 251. NATO MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL MENOPAUSAL HOT FLASHES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY COMPLEMENTARY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ESTROGEN THERAPY, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY NON-HORMONAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY ONLINE RETAILERS, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA MENOPAUSAL HOT FLASHES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)